B. AYGEN Et Al. , "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience," AASLD - TASL CONNECT REGIONAL MEETING , vol.30, pp.10-15, 2019
AYGEN, B. Et Al. 2019. Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience. AASLD - TASL CONNECT REGIONAL MEETING , 10-15.
AYGEN, B., DEMİRTÜRK, N., YILDIZ, O., ÇELEN, M. K., ÇELİK, İ., BARUT, H. Ş., ... URAL, O.(2019). Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience . AASLD - TASL CONNECT REGIONAL MEETING (pp.10-15).
AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience," AASLD - TASL CONNECT REGIONAL MEETING, 2019
AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience." AASLD - TASL CONNECT REGIONAL MEETING , pp.10-15, 2019
AYGEN, B. Et Al. (2019) . "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience." AASLD - TASL CONNECT REGIONAL MEETING , pp.10-15.
@conferencepaper{conferencepaper, author={BİLGEHAN AYGEN Et Al. }, title={Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience}, congress name={AASLD - TASL CONNECT REGIONAL MEETING}, city={}, country={}, year={2019}, pages={10-15} }